Cross-over, Double-blind, Unicentric, 52 Week Trial of Liraglutide in Type 1 Diabetes.
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Liraglutide (Primary)
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Acronyms LIDO
- 07 Jun 2017 Biomarkers information updated
- 17 Mar 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 14 Feb 2013 New trial record